A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a leading global provider of integrated, temperature-controlled supply chain solutions for the life sciences, with a strong focus on supporting the rapidly growing cell and gene therapy (“CGT”) market. Our solutions are purpose-built to support a broad range of global life sciences markets, including biopharmaceutical and pharmaceutical companies, the animal health markets, reproductive medicine, academic institutions, research, and government agencies. Our solutions help our customers ensure the safe, compliant storage, handling, and delivery of high value, temperature sensitive biological materials, including cell and gene therapies and immunotherapies. We place particular emphasis on the CGT market, our fastest growing market, by delivering highly specialized, end-to-end supply chain solutions that support cell and gene therapy programs from preclinical research, through clinical trials, and ultimately to the global commercialization of approved therapies.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 176M | 176M | 157M | 233M | 237M | 223M |
| Net Income | 70M | 70M | -123M | -108M | -45M | -284M |
| EPS | $1.40 | $1.40 | $-2.49 | $-2.21 | $-0.93 | $-6.18 |
| Free Cash Flow | -25M | -25M | -34M | -40M | -24M | -16M |
| ROIC | -12.1% | 12.9% | -21.0% | -12.4% | -4.7% | -4.1% |
| Gross Margin | 47.1% | 47.1% | 44.4% | 42.6% | 43.8% | 43.4% |
| Debt/Equity | 0.09 | 0.09 | 0.56 | 0.85 | 0.78 | 0.66 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -37M | -37M | -122M | -115M | -32M | -18M |
| Operating Margin | -20.9% | -20.9% | -77.6% | -49.4% | -13.4% | -8.0% |
| ROE | 14.0% | 15.5% | -30.5% | -22.0% | -8.2% | -44.2% |
| Shares Outstanding | 50M | 50M | 49M | 49M | 49M | 46M |
Cryoport, Inc. passes 2 of 9 quality checks, indicating weak fundamentals.
Cryoport, Inc. trades at 7.9x trailing earnings, compared to its 15-year median P/E of 15.0x, suggesting it is currently Cheap relative to its historical range. The company's 5-year average gross margin is 44.3%. Total shareholder yield (buybacks) is 2.0%.
Cryoport, Inc. (CYRX) has a current P/E ratio of 7.9, compared to its historical median P/E of 15.0. The stock is currently considered Cheap based on its historical valuation range.
Cryoport, Inc. (CYRX) has a 5-year average return on invested capital (ROIC) of -5.8%. This is below average and may indicate limited pricing power.
Cryoport, Inc. (CYRX) has a market capitalization of $500M. It is classified as a small-cap stock.
Cryoport, Inc. (CYRX) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 2.00%.
Based on historical P/E analysis, Cryoport, Inc. (CYRX) appears cheap. The current P/E of 7.9 is 47% below its historical median of 15.0.
Cryoport, Inc. (CYRX) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Cryoport, Inc. (CYRX) reported annual revenue of $176 million in its most recent fiscal year, based on SEC EDGAR filings.
Cryoport, Inc. (CYRX) has a net profit margin of 39.9%. This is a strong margin indicating high profitability.
Cryoport, Inc. (CYRX) generated $-25 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Cryoport, Inc. (CYRX) has a debt-to-equity ratio of 0.09. This indicates a conservatively financed balance sheet.
Cryoport, Inc. (CYRX) reported earnings per share (EPS) of $1.40 in its most recent fiscal year.
Cryoport, Inc. (CYRX) has a return on equity (ROE) of 15.5%. This indicates the company generates strong returns for shareholders.
Cryoport, Inc. (CYRX) has a 5-year average gross margin of 44.3%. This indicates decent pricing power.
The Ledger Terminal provides 15 years of financial data for Cryoport, Inc. (CYRX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Cryoport, Inc. (CYRX) has a book value per share of $10.01, based on its most recent annual SEC filing.